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For many years scientists have been attracted to the possibility of changing cell identity. In the last decades seminal discoveries have
shown that it is possible to reprogram somatic cells into pluripotent cells and even to transdiﬀerentiate one cell type into another.
In view of the potential applications that generating speciﬁc cell types in the laboratory can oﬀer for cell-based therapies, the next
important questions relate to the quality of the induced cell types. Importantly, epigenetic aberrations in reprogrammed cells have
been correlated with defects in diﬀerentiation. Therefore, a look at the epigenome and understanding how diﬀerent regulators can
shape it appear fundamental to anticipate potential therapeutic pitfalls. This paper covers these epigenetic aspects in stem cells,
diﬀerentiation, and reprogramming and discusses their importance for the safety of in vitro engineered cell types.
1.Introduction
The genome is organized into particular chromatin struc-
tures that have speciﬁc roles both in maintaining the overall
structure and in gene expression. The fundamental unit of
chromatin is the nucleosome, composed of two copies each
of four core histones, H2A, H2B, H3, and H4, wrapped by
146bp of DNA. The recruitment of linker histone H1 and
other structural proteins can lead to further condensation
and the of higher-order structures, which play additional
roles in the organization of chromosomes. Chromatin oﬀers
aphysicalbarriertotheeﬃcientrecruitmentandprocessivity
of the RNA Polymerase II (Poll l) and thus impedes gene
transcription [1].
The extent of chromatin condensation is subject to regu-
lation. The N-terminal tails of histones are relatively accessi-
ble to enzymatic modiﬁcations such as acetylation, methy-
lation, phosphorylation, ubiquitination, and sumoylation.
Furthermore, the cytosine residues of DNA can be modiﬁed
by methylation and hydroxymethylation. These modiﬁca-
tions can inﬂuence the degree of condensation of chromatin
per se or/and facilitate the recruitment of structural or
eﬀectorproteins,suchasremodelingcomplexes,thatdirectly
aﬀect the condensation of chromatin.
Certain areas of the genome are organized into heav-
ily condensed chromatin structures, such as centromeric
regions, and oﬀer little room for transcriptional regulation.
These areas are enriched in H3K9 methylation and marked
by the presence of structural proteins such as HP1 (hete-
rochromatin protein 1), which contribute to maintain high
levels of condensation that play mainly structural roles in the
organization of chromosomes. However, other regions of the
genomeareenrichedingenesthataresilencedbutthatcanbe
activeincertainsituationsorindiﬀerentcelltypes.Although
the mechanisms of gene silencing might be heterogeneous
and gene speciﬁc, overall these areas are occupied by the
Polycomb complex and marked with H3K27me3. Genes
encoding many developmental regulators are located in such
regions.
Tissue speciﬁc genes and developmental regulators are
thus subject to intense regulation. The mechanisms leading
to transcriptional activation or repression are presumably
gene speciﬁc and highly inﬂuenced by the transcription
factors bound at the regulatory regions of a particular gene
at a given time. Extensive genomewide studies have been
p u r s u e di na ne ﬀort to correlate transcriptional competence
and histone modiﬁcations. This rationale is the basis of the
“histone code” that postulates that the particular combina-
tion of histone modiﬁcations present at a given genomic
region acts as a code to specify gene activity [2]. However,
although certain modiﬁcations are strongly correlated with
transcriptional activation or repression, it is often diﬃcult to
predictfromthepresenceofasinglemarkthetranscriptional
s t a t u so fag e n ea n de v e nm o r ed i ﬃcult to envision the2 Comparative and Functional Genomics
predisposition of genes to become activated or repressed.
While some silent genes can be activated by certain signals
others remain permanently silent and refractory to stimu-
lation. This property is displayed in cell-speciﬁc ways and
deﬁnes both cell identity and plasticity. Certain cell types,
such as stem cells, have very plastic chromatin that makes
them extremely sensitive to environmental signals. As cells
diﬀerentiate, particular genes become silent with a conse-
quent loss of regulatory potential.
2. The Epigenetic Landmarksof ES Cells
Embryonic stem (ES) cells are derived from the inner cell
mass (ICM) of the preimplantation embryo and are char-
acterized by their ability to self-renew and to give rise to
virtuallyanycelltypeoftheadultorganism,apropertycalled
pluripotency.
Ac o n s i d e r a b l ea m o u n to fe ﬀort has been devoted to
identify the network of transcription factors that control
these two unique properties. As a result, a core regulatory
network governed by the transcription factors Oct4, Sox2,
and Nanog has been identiﬁed. These three factors are able
to stimulate the expression of each other and also to control
self-renewal and pluripotency through diﬀerent mecha-
nisms. First, they bind to the regulatory regions of genes
involved in self-renewal and stimulate their transcriptional
activity. Second, they can also occupy the regulatory regions
of critical genes involved in development and diﬀerentiation
and presumably contribute to maintain these genes in a
silencedbutpoisedstateforactivationduringdiﬀerentiation,
which constitutes the basis of pluripotency [40]. How these
factors mediate these two apparently opposite functions at
the two types of genes is intriguing. Accumulating evidence
suggests that despite the presence of self-renewal factors in
both types of genes the chromatin complexes that assemble
on these genes are completely diﬀerent [6, 13, 20, 21].
Embryonic stem cells can be maintained in vitro in
the presence of signalling molecules such as LIF, FGF, or
TGFb. While mouse ES cells are dependent on LIF, human
ES cells depend on the presence of FGF, which seems to
sustain a pluripotent state that resembles mouse stem cells
derived from the epiblasts. Overall, despite the diﬀerences
between species, all these complex and still quite unexplored
signalling events converge into two main responses: (1)
maintenance of very high rates of transcription of genes that
belong to the pluripotency network and (2) “poising” of
developmental genes.
Overall, ES cells display high rates of transcriptional
activity compared to diﬀerentiated cells [15], which is pre-
sumably devoted to the maintenance of high expression of
pluripotency genes. Accordingly, ES cells express high levels
of general transcription factors (GTFs) and of certain com-
plexes involved in transcriptional activation such as the
ATP-remodeling BAF complex and the Mediator complex
[15, 21]. Moreover, diﬀerences in the expression levels of
diﬀerent subunits of these complexes lead to the formation
of unique complexes that diﬀer in subunit composition and
potentially in function from diﬀerentiated cells [12, 21]. The
relevance of these complexes is further supported by the
reported loss of self-renewal caused by the depletion of the
remodelling factors Chd1 or Brg1 [15, 16] and the Mediator
subunit Med12 [21] in mouse ES cells. Moreover, a recent
genomewide RNAi screening revealed the involvement of
the chromatin remodelling complex INO80, the Mediator
complex, and TBP-associated factors (TAFs) in human ES
cell biology [14].S inc esomeofthesefact orsha v ebeenfound
to cooccupy the regulatory regions of self-renewal genes
with Oct4, Sox2, or Nanog [21] it is possible that they act
as cofactors that contribute to support the high levels of
transcription mediated by these pluripotency transcription
factors. Accordingly, Brg1, subunits of the INO80 complex,
and Chd1 have also been identiﬁed as part of the Oct4
interacting network [41, 42].
ESC chromatin presents structural peculiarities com-
pared to diﬀerentiated cells. Heterochromatin appears more
relaxed, perhaps due to the fact that the proteins involved
in the formation of heterochromatin such as HP1 and
linker histone H1 display hyperdynamic interactions with
chromatin [43]. ES cells also display unique modiﬁcation
patterns, referred to as bivalent domains, at the regulatory
regions of developmental genes. These are characterized
by the presence of large regions of H3K27me3 harboring
smaller regions of H3K4me3 around the transcriptional start
site. The coexistence of these two antagonistic marks has
been suggested to play a role in silencing developmental
genes in ES cells while keeping them poised for activation
upon initiation of speciﬁc developmental pathways [7, 44].
Bivalent genes are further enriched in CpG islands that in ES
cells are nonmethylated. The enzyme Tet1, which is highly
expressed in ES cells, has been suggested to maintain DNA
in a hypomethylated state through the hydroxymethylation
of CpGs at these domains [45, 46]. However, a recent
study reports that Tet1 is dispensable for maintaining
pluripotency of mouse ES cells [47]. Moreover, the function
of DNA hydroxymethylation still remains obscure regarding
its potential roles in protection against DNA methylation,
providing docking sites for given factors or as an interme-
diary of DNA demethylation.
Despite being transcribed at very low levels, bivalent
genes have considerable levels of transcriptionally engaged
RNA Polymerase II near their transcription start sites but
greatly reduced levels of productive elongating Pol ll [48].
H o w e v e r ,P o lI Ia tt h e s ep r o m o t e r si sc o n ﬁ n e dt oe x t r e m e l y
proximal regions relative to the transcription start site and is
in a conformation that is apparently diﬀerent than the one
found at bona ﬁde paused locations of actively transcribed
genes [3], suggesting that Pol II is stalled at these promoters
in a unique conformation that can be referred to as “poised.”
Knock out of Ring1B (Table 1), the Polycomb subunit that
mediates ubiquitination of histone H2A, causes the loss of
ubiquitinated H2A at bivalent genes, which in turn leads to
changes in Pol II conformation and the derepression of the
target genes. Therefore, ubiquitination of H2A seems to play
a role in restraining poised Pol II at bivalent genes [3].
The regulation and the potential role of the H3K4me3
marks at these domains remain obscure but it is likely that
members of the MLL family of H3K4 methyltransferasesComparative and Functional Genomics 3
Table 1: Chromatin- and transcription- related complexes involved in maintaining ES cells pluripotency. The main reported activity of the
complex is indicated; however, notice that speciﬁc subunits might carry out enzymatic activities diﬀerent than the main described activity.
Complex Main activity Subunit Reported function
Polycomb
PRC1
H2AK119 ubiquitination
Ring1B Restrains Pol II at bivalent genes avoiding premature diﬀerentiation [3]
CBX7 Maintenance of pluripotency regulating PRC1 targets [4]
PRC2 H3K27 methylation
Ezh2/1 Repression of diﬀerentiation genes [5]
Eed Repression of diﬀerentiation genes [5–7]
Suz12 Repression of diﬀerentiation genes and needed during diﬀerentiation [8, 9]
JARID2 Recruitment of Polycomb to target genes [10]
RBP2 Mediates H3K4me demethylation at bivalent genes [11]
BAF Nucleosome remodelling Brg1 Coactivator of the pluripotency network [12]
NuRD Nucleosome remodelling Mbd3 Nucleosome stabilization at bivalent domains [13]
INO80 Nucleosome remodelling INO80 Co-activator of the pluripotency network [14]
CHD1 Nucleosome remodelling Chd1 Co-activator of the pluripotency network [15, 16]
MLL H3K4 methylation
UTX/jmjd3 H3K27me demethylation of bivalent domains [17]
Dpy-30 Participates in the induction of developmental genes during diﬀerentiation [18]
WDR5 Co-activator of the pluripotency network [19]
CoREST Histone deacetylase LSD1 H3K4me demethylation of bivalent domains [20]
Mediator Transcription activation Med12 Co-activator of the pluripotency network [21]
(Table 1) play a role in mediating this modiﬁcation, while
its deposition might favour the recruitment of Pol II to
thesedomains [49].Knockdown ofthenewlyidentiﬁed MLL
subunit Dpy-30 [18] does not cause self-renewal defects,
but rather defects in diﬀerentiation. However, knock down
of the MLL complex core subunit WDR5 in ES cells has
been reported to induce diﬀerentiation and loss of self-
renewal [19]. More fully described is the essential role of
the Polycomb complexes in the control of these domains
(Table 1). Mouse ES cells null for speciﬁc Polycomb proteins
result in decreased H3K27 methylation and show aberrantly
induced expression of key developmental genes [6–8]. Inter-
estingly, bivalent domains seem to be tightly regulated by the
balance of activating and repressing activities. The Polycomb
complex can mediate the recruitment of the H3K4 demethy-
lase RBP2 to the bivalent domains to maintain the proper
balance of H3K4 and H3K27 methylation in mouse ES cells
[11]. Similarly, the H3K4 demethylase LSD1 is recruited to
bivalent domains to regulate the levels of H3K4 methylation
in human ES cells [20]. Moreover, subunits from the remod-
elling complexes BAF and NuRD (Brg1 and Mbd3, resp.)
antagonistically control nucleosome occupancy at bivalent
genes, with Brg1-mediated nucleosome loss associated with
gene activation, and competing nucleosome stabilization
by Mbd3 associated with gene repression. Interestingly, it
has been suggested that hydroxymethyl cytosines serve to
recruit the Mbd3/NURD complex to these domains [13].
Overall, bivalent domains appear governed by a complex
and highly dynamic equilibrium of epigenetic activators and
repressors that is likely to make them extremely sensitive to
diﬀerentiation signals.
How the enzymes that maintain the bivalent domains in
ES cells are recruited or stabilized at these particular
regions is not fully understood. In Drosophila, the Polycomb
complex is able to bind to speciﬁc DNA sequences [50].
This mechanism seems not to apply to mammalian cells,
but some reports highlight the possibility that the extremely
conserved distribution of CpG domains in the regulatory
regions of developmental genes play a role in the recruitment
of the Polycomb complex [51, 52]. Moreover, Tet1 has been
reported to facilitate the chromatin binding of Polycomb
components likely by decreasing DNA methylation levels
at CpG-rich domains [53]. It is also possible that speciﬁc
transcription factors that bind the regulatory regions of
bivalent genes such as Oct4, Sox2, and Nanog contribute to
Polycomb recruitment or stabilization. Accordingly, Nanog
and Oct4 have been described to interact with complexes
involved in transcriptional repression, including Polycomb
subunits [41, 54]. Also, the transcription factor JARID2
has been suggested to participate in the recruitment of
the Polycomb complex PRC2 to the regulatory regions of
developmental regulators in mouse ES cells [10].
3. Epigenetic Changes duringDifferentiation
The in vitro diﬀerentiation of ES cells is achieved through
the removal of molecules that promote self-renewal, such as
LIF or FGF, and the addition of factors that induce diﬀeren-
tiation. These changes in culture conditions lead to down-
regulation of the pluripotency network and to the activation
orrepressionofdevelopmentalgenesinagerm-layer-speciﬁc
fashion.
Ultimately, the physiological function of bivalent do-
mains might be to maintain important regulatory sequences
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are activated by the diﬀerentiation signals. The regulatory
areas, which were accessible at the undiﬀerentiated stage,
and which are not targeted by transcription factors, “close
up” during diﬀerentiation becoming further inaccessible
[55]. Therefore, diﬀerentiation to one particular lineage
implies the permanent and irreversible silencing of genes
involved in alternative lineages. Bivalent domains tend to
resolve into methylated H3K4 alone for those genes that will
become activated or methylated H3K27 alone for those that
will be repressed during diﬀerentiation [56, 57]. Repression
might be further reinforced by the incorporation of other
repressive marks such as H3K9me3 or DNA methylation
[58] ensuring the permanent silencing of developmental
genes. The resolution of bivalent domains requires the
coordinated action of histone lysine methyltransferases and
demethylases. An elegant example is the role of H3K27
demethylates UTX and Jmjd3 in the activation of Hox genes
during development [17] and in neuronal commitment
[59]. Both demethylases are associated with MLL complexes
[60,61],suggestingthatremovaloftheH3K27me3markand
maintenance of the H3K4me3 at bivalent genes that become
activated during diﬀerentiation are coordinated events.
Importantly, a signiﬁcant number of bivalent domains can
remain unresolved and new bivalent genes might appear
after diﬀerentiation [56], which might have consequences
for the degree of plasticity that adult cells display.
Changes in subunit composition of chromatin-related
complexes might also contribute to establishing the new
epigenetic landscapes of diﬀerentiated cells. Such is the case
of the Cbx subunits of the Polycomb complex. During
diﬀerentiation, the expression of Cbx7 is down-regulated,
while Cbx2, Cbx4, and Cbx8 are induced, leading to changes
in the complex composition and properties [4]. In a similar
fashion, changes in the expression of histone variants might
also be involved in establishing the appropriate patterns
of gene expression during diﬀerentiation. As an example,
histone linker variant H1.0 is induced during diﬀerentia-
tion and speciﬁcally recruited to the regulatory regions of
pluripotency and developmental genes, contributing to their
repression [62].
Thesilencingofthegenesthatbelongtothepluripotency
network is a critical event for proper diﬀerentiation. These
genes become passively down-regulated due to the absence
of LIF or FGF signalling and more actively due to the
action of transcriptional repressors that are induced during
diﬀerentiation. As a result, several mediators of repression
are recruited to these genes, such as the methyltransferase
G9a that has been reported to participate in the silencing of
Oct4 by mediating methylation at H3K9 and contributing
to the recruitment of HP1 and establishment of DNA
methylation [63, 64]. The fact that in diﬀerentiated cells the
regulatory regions of diﬀerent genes of the pluripotency net-
work are marked with diﬀerent combinations of repressive
modiﬁcations [58] further suggests that the mechanisms and
epigenetic regulators that participate in their repression are
likely to be gene speciﬁc.
4. Walking Back the Epigenetic
RoadduringReprogramming
N u c l e a rt r a n s f e re x p e r i m e n t s[ 23] showed for the ﬁrst time
that it is possible to reverse the diﬀerentiated phenotype.
More recently, it became possible to generate induced
pluripotent stem cells (iPSCs) from somatic cells by overex-
pressingspeciﬁctranscriptionfactors,mostcommonlyOct4,
Sox2, Klf4, and c-Myc [24]. How these transcription factors
impinge on the somatic cell genome to reprogram its gene
expression proﬁle is still not clear, but the low eﬃciency of
the process suggests that somatic cells present barriers that
prevent switches in cell identity. The fact that the eﬃciency
of reprogramming can be increased by using inhibitors
of DNA methyltransferases, histone methyltransferases and
deacetylases [65–67] points to a critical role of chromatin as
a barrier that prevents reprogramming.
Reprogramming appears to be a gradual process in
which in early stages cells acquire the ability to self-renew
and downregulate cell speciﬁc programs [68]. At this stage,
cells can be trapped in a partially reprogrammed state
in which they self-renew and continue to depend on the
expression of the transgenes. A second critical phase consists
of the activation of the endogenous pluripotency network,
includingthegenesOct4,Sox2,andNanog.Thiseventallows
the maintenance of pluripotency in an autonomous way
and independently of the transgenes. However, this stage
is reached at a low frequency likely due to the inability of
the transfactors to bind and activate the regulatory regions
of the endogenous pluripotency genes [68]. Although the
ﬁrst stages of reprogramming lead to down-regulation of
the expression of cell-speciﬁc genes, the complete erasure
of this transcriptional memory takes place gradually after
theactivationofthepluripotencynetwork[69].Importantly,
bivalent domains need to be re-established at critical devel-
opmental genes. Failure to regain this permissive status has
dramatic consequences for diﬀerentiation, as found in iPSCs
derived from nonhaematopoietic cells that display impaired
blood-forming potential due to residual DNA methylation
at loci required for diﬀerentiation into the haematopoietic
lineage [70]. Moreover, the aberrant expression of bivalent
genes in mouse iPSCs can be inversely correlated with
their ability to give rise to viable animals by tetraploid
complementation [71].
Two recent studies suggest that reprogramming factors
ﬁrst target regions of the genome that are in a permissive
chromatinconformationinsomaticcells(Figure 1).Kocheet
al.[72]analyzedtheexpressionpatternsandepigeneticland-
scapesofﬁbroblastsatveryearlystagesofreprogramming.At
this phase,changesin geneexpression seem limited to down-
regulation of the somatic speciﬁc program, even though
epigenetic changes can be readily detected at promoters that
are already in an open and accessible conformation. Most
conspicuous early event consists of the gain of H3K4me2 at
promoters that are typically marked with H3K4me3 in ES
cells, such as certain pluripotency and early developmental
genes. These changes are restricted to sites of high CpG
density, which are devoid of DNA methylation both in
ﬁbroblasts and ES cells, and in which reprogrammingComparative and Functional Genomics 5
M
OCT4
Developmental
and early pluripotency genes  
O O
K
O O
K K
S
On Off
Developmental
Early
pluripotency
Developmental
Poised
Primed
Late  pluripotency
On
Pluripotency
EP
Poised
Developmental
On
Developmental
Early Intermediate Late
Off
Primed
M
O
K
S
Early
pluripotency
M
OCT4
evelopmental
nd early pluripotency genes 
K K
On Off
Developmental
Early ly rl ar E
pluripotency
Developmental
Poised
Primed
Late  pluripotency
On
Pluripotency
P P E
Developmental Developmental
Off
Primed
M M M
O O
K
O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O O
K K K K K K
S S S S
Early l
pluripotency
Figure 1: Epigenetic changes during reprogramming in genes containing CpG islands. Pluripotency and developmental genes have high
CpG content and suﬀer dramatic changes during reprogramming. The reprogramming factors (OSKM, Oct4, Sox2, Klf4, and c-Myc) target
preferentially the permissive enhancers of Polycomb target genes that are devoid of DNA methylation. These include silent developmental
genes and perhaps pluripotency genes that respond early to the transfactors. As a result these genes gain H3K4 methylation at proximal
promoters and are primed to become poised (developmental genes) or active (pluripotency genes) at latter stages. The products of early
pluripotency (EP) genes might contribute to activate, together with the transfactors, late pluripotency genes marked with DNA methylation,
such as Oct4. Finally, developmental genes become poised by gain of H3K27 methylation. Permissive enhancers are represented as dotted
lines. Red ﬂags denote H3K27me3. Green ﬂags denote H3K4me1 (one ﬂag), H3K4me2 (two ﬂags), and H3K4me3 (three ﬂags). Circles
correspond to unmethylated (open) or methylated (ﬁlled) CpG islands.
factor regulatory motifs might be present. Using a diﬀerent
approach, Taberlay et al. [73] describe that developmental
genes marked with H3K27me3 at their promoters contain
permissive enhancers that are depleted of nucleosomes and
marked with H3K4me1 in somatic cells. These enhancers are
likely to be targeted by the reprogramming factors at initial
stages of reprogramming.
In contrast, the gain of DNA hypermethylation typical
of ES cells and the reestablishment of H3K27me3 at bivalent
promoterstakeplacelateinthereprogrammingprocess[72].
Therefore, the acquisition of the facultative heterochromatin
typical of ES cells might be a late critical step that cells need
to overcome during reprogramming. Indeed the silencing
of tissue speciﬁc genes appears to be more important than
previously thought for the process of reprogramming, as
suggested by the discovery that somatic cells can be fully
reprogrammed to pluripotency by overexpression of the
miR-302/367 cluster alone [36].
5. Discordances betweenESand IPSCells
The process of somatic cell reprogramming generates cells
with similar properties to ES cells but an important question
still remains: how similar are iPS and ES cells? Studies
looking at global gene expression and the epigenome suggest
that they are in fact quite similar and that iPS cells are
unequivocally diﬀerent from the somatic cells of origin
[74, 75]. However, particular diﬀerences have been identiﬁed
whose signiﬁcance remains to be determined [37, 76]. The
comparison between ES and iPS cells is not straightforward
fortwomainreasons:(1)EScellsthemselvesshowvariability
between lines; (2) the diﬀerent strategies to generate iPS
cells and culture techniques used in diﬀerent laboratories
make it diﬃcult to tease out as to which diﬀerences are
due to variations in experimental procedures and which are
intrinsic to iPS cells.
Reﬂecting the gradual nature of the reprogramming pro-
cess, early passage iPS cells retain residual expression of6 Comparative and Functional Genomics
genes from the cell of origin, which has been proposed
to facilitate their diﬀerentiation back into those very same
cell types [69, 77]. However, the expression of these genes
tends to disappear at late passages [69, 78]. Importantly, it
has been described that a certain number of genes are still
diﬀerentially expressed in several lines of iPS cells at late
passages [76], although the consequences of this diﬀerential
expression still need to be addressed.
More important is perhaps the potential diﬀerences in
theepigenomesofiPSandEScells,sincethisislikelytoinﬂu-
ence the ability of cells to diﬀerentiate and the quality of the
ﬁnal diﬀerentiated products. Regarding DNA methylation
at CpGs, genome-wide analyses revealed that a signiﬁcant
number of developmental genes retained signiﬁcant levels
of DNA methylation at their regulatory regions in early
passage iPS cells [79]. However, a very similar methylation
proﬁle between ES cells and iPSC was found in these
genes at late passages [37]. Overall, iPS cells show a few
hundred diﬀerentially methylated regions when compared
to ES cells, corresponding both to somatic memory and to
aberrant methylation [37, 79]. Diﬀerent iPS cell lines share
only a small number of diﬀerentially methylated regions,
suggestingthatthereissigniﬁcantreprogrammingvariability
with regard to DNA methylation. However, some hot spots
of shared diﬀerential methylation between lines have been
found [37, 76]. More speciﬁcally, defective re-establishment
of DNA methylation at particular loci that correlates with
sustained expression of a few somatic genes has been
reported [76]. Regarding non-CpG DNA methylation, iPS
cells show hypomethylation in large regions proximal to
centromeres and telomeres compared to ES cells [37]. Since
the role of non-CpG DNA methylation is not clear, it is
diﬃcult to predict the potential outcome of this diﬀerence. A
recent comprehensive study [74] combined analysis of global
gene expression and DNA methylation in undiﬀerentiated
and diﬀerentiated cells to score for the ability of human
ES and iPS cells to diﬀerentiate into certain lineages. The
authors concluded that no common distinctive pattern was
shared by all iPS cell analyzed and that reprogrammed cells
were not functionally distinguishable from ES cells.
6.FutureGoal:Assess the Epigenetic
Stabilityto EnsureSafety
The prospect of potential uses of iPS cells in autologous
therapies made researchers rush into the development of
nonintegrative approaches to deliver the lowest number
of factors into somatic cells [80]( Table 2). However, the
idea that the absence of viral integrations would make
these cells safe for therapy appears na¨ ıve if we take into
account two main facts. First, iPS cells are expected to have
the same drawbacks of ES cells, that is, the generation of
diﬀerentiated products that are plastic enough to integrate
into the damaged tissues but diﬀerentiated enough to avoid
the formation of tumors. Second, iPS cells not only display
epigenetic aberrancies but they also have accumulated a
number of genetic mutations during reprogramming and
expansion in culture [38, 39].
Table 2: Main breakthroughs regarding reprogramming and trans-
diﬀerentiation of somatic cells. The need of oocytes and the low
eﬃciency of nuclear transfer in humans have propitiated the search
for alternative strategies to generate pluripotent cells. Induced
pluripotentcells,initiallyobtainedwithretrovirusesencodingOct4,
Sox2, Klf4 and c-Myc (OSKM), were considered unsafe for therapy
due to the presence of viral integrations and the use of oncogenes
Klf4 and c-Myc. Therefore, a major rush to develop non integrative
methods and to avoid the use of oncogenes started. However,
the ﬁnding that iPS cells have epigenetic and genetic aberrations
suggests that these cells will need to be analyzed in detail before
moving to the clinic.
Year Breakthrough
1987 Fibroblast transdiﬀerentiation to muscle cells [22]
1997 Pluripotent cells by nuclear transfer [23]
2006 Mouse iPS cells with OSKM retroviruses [24]
2007 Human iPS cells with OSKM retroviruses [25]
2008
IPS cells without c-Myc [26]
iPS cells from neural stem cells with two factors [27]
iPS cells with two factors and small molecules [28]
iPS cells with non integrative viruses [29]
Desease-speciﬁc iPS cells [30]
2009 iPS cells with proteins [31]
2010
iPS cells with RNA [32]
Transdiﬀerentiation of ﬁbroblasts to neurons or to
cardiomyocytes [33, 34]
Transdiﬀe r e n t i a t i o no fﬁ b r o b l a s t st ob l o o dc e l l s[ 35]
2011
iPS cells with miRNAs [36]
iPS cells have epigenetic aberrations [37]
iPS cells have genetic aberrations [38, 39]
Laboratories around the world have now started to
generate therapeutic cell types by transdiﬀerentiation, such
as blood, neurons, or cardiomyocytes from ﬁbroblasts [33,
81, 82]. Assessing the similarity of these cells or the ones
obtained from pluripotent cells to their in vivo counterparts
is not straightforward. Moreover, it is likely that these cells
obtained in vitro diﬀer signiﬁcantly from those found in
the body. But perhaps more important is to understand the
potential adverse aﬀects that these cells can cause. Important
questions emerge. How stable are these newly induced
programs? What is the probability that the transplanted cells
revert to less diﬀerentiated and proliferative phenotypes?
Importantly,transdiﬀerentiationisoftendrivenbytheaction
of master transcriptional regulators or pioneer transcription
factors able to induce whole new programs of gene expres-
sion. These master genes, which might be also regulated
during early stages of reprogramming [73], are targets of
Polycomb and are enriched in CpG islands that are usually
DNA hypomethylated in normal tissues but become often
hypermethylated in cancer [79, 83] and during aging [84].
This suggests that regions of the genome that are subject to
intense regulation and that play important roles in deﬁning
cell identity might be also more likely to suﬀer pathological
deregulation.Comparative and Functional Genomics 7
The answer to the above questions unequivocally lies
in the epigenome and how the regulators of the epigenetic
marks can secure the stability of the newly established epige-
netic programs. A better characterization of the epigenetic
landscape, including the identiﬁcation of critical genomic
areas with tendency to suﬀer aberrant or unstable epigenetic
reprogramming and the activities involved in their regula-
tion, will be needed in order to predict the safety of the
induced cell types.
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